Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,148.97 9.71 0.31%
FTSE 100 6,610.90 26.73 0.41%
DAX 9,381.58 63.76 0.68%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

Daiichi Sankyo, Inc. Makes Two New Executive Appointments



          Daiichi Sankyo, Inc. Makes Two New Executive Appointments

PR Newswire

PARSIPPANY, N.J., Oct. 3, 2013

PARSIPPANY, N.J., Oct. 3, 2013 /PRNewswire/ -- Daiichi Sankyo, Inc. today
announced that Glenn Gormley, MD, PhD, has been named corporate President and
Chairman of Daiichi Sankyo, Inc.  Dr. Gormley will also continue in his
existing roles as President, Daiichi Sankyo Pharma Development, Global Head of
Research and Development and Senior Executive Officer of Daiichi Sankyo, Co.
Ltd.  In addition, Greg Barrett has been appointed as the new acting head of
the Commercial Division of Daiichi Sankyo, Inc. in the U.S.  Both appointments
are effective as of October 3, 2013.  

Daiichi Sankyo, Inc.'s former President and CEO, and head of its Commercial
Division, John Gargiulo, has left the company effective October 3, 2013.

Greg Barrett will hold the new title of Acting President, Daiichi Sankyo
Administrative & Commercial Operations.  In this role, Mr. Barrett will be
responsible for leading the Daiichi Sankyo U.S. Commercial Division including
marketing, sales and supply chain operations in the U.S. organization.  Mr.
Barrett most recently held the position of Vice President, Marketing and
Managed Markets, at Daiichi Sankyo, Inc. and has been with the company since
the late 1990's.

About Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative
pharmaceutical products to address the diversified, unmet medical needs of
patients in both mature and emerging markets. While maintaining its portfolio
of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial
infections, the Group is engaged in the development of treatments for
thrombotic disorders and focused on the discovery of novel oncology and
cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has
created a "Hybrid Business Model," which will respond to market and customer
diversity and optimize growth opportunities across the value chain. For more
information, please visit: www.daiichisankyo.com.

Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of
the Daiichi Sankyo Group.  For more information on Daiichi Sankyo, Inc.,
please visit www.dsi.com.

SOURCE Daiichi Sankyo, Inc.

Website: http://www.dsi.com
Contact: Kim Wix, Senior Director, Public Affairs, Daiichi Sankyo, Inc.,
973-944-2338 office 908-656-5447 mobile
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement